Journal of Hepatology
Volume 50, Issue 6 , Pages 1247-1257 , June 2009

Operational tolerance after liver transplantation

  • Giuseppe Orlando

      Affiliations

    • Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, Headington, Oxford OX3 9DU, UK
    • Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA
    • Corresponding Author InformationCorresponding author. Tel.: +44 505 272 5593; fax: +44 505 272 3518.
    • ,
  • Shay Soker

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA
    • ,
  • Kathryn Wood

      Affiliations

    • Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, Headington, Oxford OX3 9DU, UK

References 

  1. Merrill JP, Murray JE, Harrison JH. Successful homotransplantation of the human kidney between identical twins. JAMA. 1956;160:277–282
  2. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172:603–606
  3. Ashton-Chess J, Giral M, Brouard S, Soulillou JP. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation. 2007;84:1215–1219
  4. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology. 1993;17:1127–1152
  5. Reyes J, Zeevi A, Ramos H, Tzakis A, Todo S, Demetris AJ, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc. 1993;25:3315–3319
  6. Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transpl Proc. 1995;27:207–209
  7. Ramos HC, Reyes J, Abu-Elmagd K, Zeevi A, Reinsmoen N, Tzakis A, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation. 1995;59:212–217
  8. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997;63:243–249
  9. Tzakis AG, Reyes J, Zeevi A, Ramos H, Nour B, Reinsmoen N, et al. Early tolerance in pediatric liver allograft recipients. J Pediatr Surg. 1994;29:754–756
  10. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol. 2007;17:114–119
  11. Thomson AW, Mazariegos GV, Reyes J, Donnenberg VS, Donnenberg AD, Bentlejewski C, et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation. 2001;72(8 Suppl):S13–S22
  12. Mazariegos GV, Zahorchak AF, Reyes J, Ostrowski L, Flynn B, Zeevi A, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant. 2003;3:689–696
  13. Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson AW. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant. 2005;5:314–322
  14. Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation. 2008;85:369–377
  15. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology. 1998;27:926–933
  16. Girlanda R, Rela M, Williams R, O’Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc. 2005;37:1708–1709
  17. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest. 2000;106:145–155
  18. Geissler F, Jankowska-Gan E, DeVito-Haynes LD, Rhein T, Kalayoglu M, Sollinger HW, et al. Human liver allograft acceptance and the “tolerance assay: in vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression. Transplantation. 2001;72:571–580
  19. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3:199–210
  20. Takatsuki M, Uemoto S, Inomata Y, Sakamoto S, Hayashi M, Ueda M, et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol. 2001;8:279–286
  21. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001;72:449–454
  22. Koshiba T, Li Y, Takemura M, Wu Y, Sakaguchi S, Minato N, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol. 2007;17:94–97
  23. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 2004;4:2118–2125
  24. Yoshizawa A, Ito A, Li Y, Koshiba T, Sakaguchi S, Wood KJ, et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc. 2005;37:37–39
  25. Pons JA, Yélamos J, Ramı´rez P, Oliver-Bonet M, Sánchez A, Rodrı´guez-Gago M, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003;75:1045–1047
  26. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl Imm. 2007;17:108–113
  27. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol. 2006;44:702–709
  28. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergat Weaning Off Immunosuppression Trial in HCV liver transplant patients. The updated follow up at 78 months. Transpl Imm. 2008;20:43–47
  29. Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation. 2003;76:1699–1704
  30. Gras J, Wieërs G, Vaerman JL, Truong DQ, Sokal E, Otte JB, et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl. 2007;13:426–433
  31. Hsu LW, Goto S, Nakano T, Lai CY, Lin YC, Kao YH, et al. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants. Transpl Immunol. 2007;17:137–146
  32. Alexander SI, Smith N, Hu M, Verran D, Shun A, Dorney S, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med. 2008;358:369–374
  33. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502–1510
  34. Trzonkowski P, Zilvetti M, Chapman S, Wieckiewicz J, Sutherland A, Friend P, et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant. 2008;8:338–347
  35. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation – efficacy and safety at five years. Am J Transplant. 2005;5:1347–1353
  36. Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery. 2004;136:754–760
  37. Agarwal A, Shen LY, Kirk AD. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transpl Immunol. 2008;20:6–11
  38. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76:120–129
  39. Ciancio G, Burke GW. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant. 2008;8:15–20
  40. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk?. Transplantation. 2005;79:1157–1159
  41. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation. 2006;82:1342–1351
  42. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5:465–474
  43. Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation. 2007;83:1571–1576
  44. Assy N, Adams PC, Myers P, Simon V, Ghent CN. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut. 2007;56:304–306
  45. Persson H, Friman S, Scherstén T, Svanvik J, Karlberg I. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet. 1990;336:52–53
  46. Matthes-Martin S, Peters C, Königsrainer A, Fritsch G, Lion T, Heitger A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood. 2000;96:3997–3999
  47. Mellgren K, Fasth A, Saalman R, Olausson M, Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol. 2005;84:755–757
  48. Donckier V, Troisi R, Toungouz M, Colle I, Van Vlierberghe H, Jacquy C, et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl Immunol. 2004;13:139–146
  49. Donckier V, Troisi R, Le Moine A, Toungouz M, Ricciardi S, Colle I, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl. 2006;12:1523–1528
  50. Craciun L, Stordeur P, Troisi R, Le Moine A, Toungouz M, Colle I, et al. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specific hyporesponsiveness. Transplant Proc. 2007;39:2665–2667
  51. Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant. 2005;5:608–613
  52. Mathew JM, Garcia-Morales RO, Carreno M, Jin Y, Fuller L, Blomberg B, et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol. 2003;11:307–321
  53. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc. 1970;2:489–496
  54. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando). 2008;22:262–273
  55. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509–525
  56. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. NEJM. 2008;358:353–361
  57. Urban CH, Deutschmann A, Kerbl R, Lackner H, Schwinger W, Königsrainer A, et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;30:535–537
  58. Kadry Z, Mullhaupt B, Renner EL, Bauerfeind P, Schanz U, Pestalozzi BC, et al. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation. 2003;76:1003–1006
  59. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med. 2004;350:2624–2625
  60. Martı´nez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008;118:2845–2857
  61. Martı´nez-Llordella M, Puig-Pey I, Orlando G, Tisone G, Ramoni M, Lerut J, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transpl. 2007;7:309–319

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00169-X

doi: 10.1016/j.jhep.2009.03.006

Journal of Hepatology
Volume 50, Issue 6 , Pages 1247-1257 , June 2009

Article Tools